North America Pharmacogenomics Market Size, Share & Trends Analysis Report By Technology (PCR, Sequencing, Microarray, Gel electrophoresis, Mass Spectrometry, Other technologies), By Application (Drug discovery, Cancer, Neurology and psychiatry, Pain management, Cardiovascular disorders, Others), By End-User (Hospitals and clinics, Biopharmaceutical firms, CROs and CDMOs, Others) and By Country(US, Canada) Forecasts, 2024-2032

Market Overview

The North America pharmacogenomics market is expected to reach USD 6696.59 million by 2030, with a CAGR of 8.46%.

In pharmacogenomics, genes are studied concerning drug response. This field combines pharmacology (the science of pharmaceuticals) and genomics (the study of genes and their functions) to create effective, safe treatments depending on a person's genetic composition.

Many medications on the market today are "one size fits all," but they don't work the same for everyone. It's difficult to tell who will benefit from a drug and who will have side effects (called adverse drug reactions). Adverse medication reactions cause a considerable number of hospitalizations and deaths.

Researchers are trying to figure out how genetic variations affect the body's response to drugs. These genetic distinctions will be utilized to forecast whether a treatment will be successful for a specific person and which dosage will help avoid unpleasant drug reactions. Conditions like clopidogrel resistance, warfarin sensitivity, warfarin resistance, malignant hyperthermia, Stevens-Johnson syndrome/toxic epidermal necrolysis, and thiopurine S-methyltransferase deficiency can change how a person responds to certain medicines.

The science of pharmacogenomics is expanding, and clinical studies are testing new approaches. Pharmacogenomics will be utilized in the future to develop personalized medications to treat a variety of diseases, including cardiovascular disease, Alzheimer's disease, cancer, and asthma.

Market Dynamics

Drivers

The incessant need for treatments of debilitating diseases such as cancer is the primary force behind the expansion of the market

The increased prevalence of diseases like cancer, which have no apparent cure or treatment plan advised by medical research, is driving the market. As a result, in the last decade, genomics and precision medicine have become increasingly important in the treatment of cancer patients.

In contrast to other illnesses, cancer therapy must consider both acquired (somatic) and inherited (germline) variation, which affects a drug's efficacy and safety. As a result, PGx tests have been widely used to identify treatment options.

Growing concerns about Adverse Drug Reactions (ADRs) have boosted the market significantly

In today's healthcare system, adverse pharmaceutical responses are a problem for doctors worldwide. One patient may experience adverse side effects while another does not. As a result, a community's diversity creates unanticipated reactions, impeding the existing healthcare market scenario. Many pharmaceuticals have life-threatening side effects in patients. According to FDA data from 2018-2019, 6.7% of hospitalized patients experienced an adverse medication reaction, with a 0.32 per cent death rate. According to these estimates, there are around 2,216,000 severe ADRs in hospitalized patients each year, resulting in over 106,000 deaths.

North America Pharmacogenomics market solutions are a unique solution to the issue. Understanding the underlying biological mechanisms and exploiting genetic contributions for customized therapy is the core goal of pharmacogenomics.

Restraints

These are some of the issues hindering the market growth of pharmacogenomics

• Infrastructure

Infrastructure is one of the significant roadblocks to clinical pharmacogenomics. The ethical and political frameworks, the re-education of many different groups in the health sector, and the physical infrastructure for pharmacogenomic tests are all part of this. These obstacles are not exclusive to pharmacogenomic tests. After the general infrastructure has been put up for a single pharmacogenomic test, subsequent tests will only necessitate minimal infrastructure changes. Making a case for the initial investment is the issue.

• Education

A lack of healthcare professional education hampers the widespread use of pharmacogenomics. A perceived shortage of pharmacogenomic education is hampering Pharmacogenomics' market expansion among various health care practitioners.

• Ethical issues

Many people have expressed concerns regarding the ethical implications of using genetic data in medicine. This is perhaps more important in the context of pharmacogenomics for genetic testing that predicts efficacy rather than adverse outcomes. The three primary categories of ethical dilemmas are the equitable provision of healthcare, the possibility that genetic polymorphisms may track with race or ethnicity, and the considerations of consent, access, and privacy surrounding pharmacogenomic information.

Regional Analysis

The market is divided into the U.S, Canada & Mexico, based on country.

The North American regional market for pharmacogenomics is the largest in terms of revenue. Several factors are driving the market, including the incidence of chronic diseases, particularly cancer, and increased end-user awareness of the use and benefits of pharmacogenomics, among others.

Over eleven initiatives in the United States have received government and private sector funding in the previous ten years. The following is a selection of the most important projects:

• The Translational Pharmacogenomics Program, for example, was designed by the U.S. Pharmacogenomics Research Network to combine pre-emptive pharmacogenomic testing in many clinical settings in a real-world scenario.
• Another critical project is the University of Chicago's 1200 Patients Project, which attempted to determine the feasibility and benefit of implementing pre-emptive pharmacogenomic testing of a panel of genes. It also wanted to know how giving pharmacogenomics test findings affected prescriptions, physician decisions, and patient outcomes.

These activities and programmes had a tremendous impact on the market, particularly in North America, and helped to fuel its rise. Furthermore, the market is supported by increased healthcare budgets and end-users spending, which helps balance the regional market dynamics.

Segmental Analysis

The North America pharmacogenomics market is divided into PCR, sequencing, microarray, gel electrophoresis, mass spectrometry, and other technologies based on technology. The PCR market is divided into real-time, regular, and digital PCR. In 2021, the PCR category accounted for the most significant share of the pharmacogenomics market.

The North America pharmacogenomics market is divided into drug discovery, cancer, neurology and psychiatry, pain management, cardiovascular disorders, and others, depending on the application. In 2021, the oncology segment held the highest market share. However, the drug discovery category is predicted to have the highest CAGR during the projection period.

The pharmacogenomics market is divided into hospitals and clinics, biopharmaceutical firms, CROs and CDMOs, and others, depending on the end-user. In 2021, the CROs and CDMOs categories held the most market share, while the hospital and clinic segment is predicted to grow fastest throughout the forecast period.

Impact of covid-19

Recent Developments

• May 2022, The FreeStyle Libre 3 system, which is the next generation of the world's best continuous glucose monitor (CGM), is now approved by the U.S. Food and Drug Administration for diabetes patients in the U.S. aged four and up.
• The Food and Drug Administration (FDA) in the United States approved expanding the indication for CardioMEMS from people with advanced (Class III) heart failure to those in the early stages of the disease (Class II), as well as patients who have a blood test that shows elevated levels of specific biomarkers that indicate worsening heart failure, in February 2022.
• According to Roche (SMA), in May 2022, The FDA approved a label extension for Evrysdi® (risdiplam) to include babies under the age of two months who have spinal muscular atrophy, according to Roche (SMA).
• In May of 2022, New pivotal data on Roche's investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting on June 3-7 and the European Hematology Association (EHA) 2022 Congress on June 9-12.